^
    Back
    Association details:
    Biomarker:CCNE1 amplification
    Cancer:Ovarian Cancer
    Drug:lunresertib (RP-6306) (PKMYT1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    RP-6306 in Patients With Advanced Cancer

    Excerpt:
    ...- Tumour must be HER-2+ (IHC 3+, or FISH+) and have CCNE1 amplification...
    Trial ID:
    NCT05605509
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    5650 - RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in CCNE1 amplified cancer cells

    Published date:
    03/09/2022
    Excerpt:
    In combination with gemcitabine, RP-6306 demonstrated tumor regression and superior efficacy compared to single agent treatment of either agent alone in multiple CCNE1 amplified models, including HCC1569 and OVCAR3....Our studies show that inhibition of PKMYT1 kinase activity impairs the growth of CCNE1 amplified cancer cell lines both in vitro and in vivo and stands to benefit cancer patients with CCNE1 amplification.
    Secondary therapy:
    gemcitabine